288 related articles for article (PubMed ID: 16455650)
1. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.
Kisselev AF; Callard A; Goldberg AL
J Biol Chem; 2006 Mar; 281(13):8582-90. PubMed ID: 16455650
[TBL] [Abstract][Full Text] [Related]
2. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.
Kisselev AF; Garcia-Calvo M; Overkleeft HS; Peterson E; Pennington MW; Ploegh HL; Thornberry NA; Goldberg AL
J Biol Chem; 2003 Sep; 278(38):35869-77. PubMed ID: 12815064
[TBL] [Abstract][Full Text] [Related]
3. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates.
Kisselev AF; Goldberg AL
Methods Enzymol; 2005; 398():364-78. PubMed ID: 16275343
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites.
Britton M; Lucas MM; Downey SL; Screen M; Pletnev AA; Verdoes M; Tokhunts RA; Amir O; Goddard AL; Pelphrey PM; Wright DL; Overkleeft HS; Kisselev AF
Chem Biol; 2009 Dec; 16(12):1278-89. PubMed ID: 20064438
[TBL] [Abstract][Full Text] [Related]
5. Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings.
Kisselev AF; Kaganovich D; Goldberg AL
J Biol Chem; 2002 Jun; 277(25):22260-70. PubMed ID: 11927581
[TBL] [Abstract][Full Text] [Related]
6. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown.
Kisselev AF; Akopian TN; Castillo V; Goldberg AL
Mol Cell; 1999 Sep; 4(3):395-402. PubMed ID: 10518220
[TBL] [Abstract][Full Text] [Related]
7. [Extracellular proteasomes purification methods and the evaluation of proteasomal peptidase activities].
Zaĭkova IuIa; Kulichkova VA; Mitenkova KA; Tsimokha AS
Tsitologiia; 2014; 56(6):427-32. PubMed ID: 25696979
[TBL] [Abstract][Full Text] [Related]
8. Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity.
Wilkins OM; Downey SL; Weyburne ES; Williams DA; Mirabella AC; Overkleeft HS; Kisselev AF
Anal Biochem; 2014 Apr; 451():1-3. PubMed ID: 24486333
[TBL] [Abstract][Full Text] [Related]
9. Nature of pharmacophore influences active site specificity of proteasome inhibitors.
Screen M; Britton M; Downey SL; Verdoes M; Voges MJ; Blom AE; Geurink PP; Risseeuw MD; Florea BI; van der Linden WA; Pletnev AA; Overkleeft HS; Kisselev AF
J Biol Chem; 2010 Dec; 285(51):40125-34. PubMed ID: 20937826
[TBL] [Abstract][Full Text] [Related]
10. Activation of Chymotrypsin-Like Activity of the Proteasome during Ischemia Induces Myocardial Dysfunction and Death.
Sanchez G; Berrios D; Olmedo I; Pezoa J; Riquelme JA; Montecinos L; Pedrozo Z; Donoso P
PLoS One; 2016; 11(8):e0161068. PubMed ID: 27529620
[TBL] [Abstract][Full Text] [Related]
11. Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a nonprocessive pathway.
Cardozo C; Michaud C
Arch Biochem Biophys; 2002 Dec; 408(1):103-10. PubMed ID: 12485608
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous fluorescent monitoring of proteasomal subunit catalysis.
Wakata A; Lee HM; Rommel P; Toutchkine A; Schmidt M; Lawrence DS
J Am Chem Soc; 2010 Feb; 132(5):1578-82. PubMed ID: 20078037
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human and yeast 20S proteasome by analogues of trypsin inhibitor SFTI-1.
Dębowski D; Pikuła M; Lubos M; Langa P; Trzonkowski P; Lesner A; Łęgowska A; Rolka K
PLoS One; 2014; 9(2):e89465. PubMed ID: 24586798
[TBL] [Abstract][Full Text] [Related]
14. (19)F NMR monitoring of the eukaryotic 20S proteasome chymotrypsin-like activity: an investigative tool for studying allosteric regulation.
Keita M; Kaffy J; Troufflard C; Morvan E; Crousse B; Ongeri S
Org Biomol Chem; 2014 Jul; 12(26):4576-81. PubMed ID: 24867821
[TBL] [Abstract][Full Text] [Related]
15. Identification of Novel Proteasome Inhibitors from an Enaminone Library.
Elliott ML; Thomas K; Kennedy S; Koduri ND; Hussaini RS; Sheaff RJ
Chem Biol Drug Des; 2015 Sep; 86(3):322-32. PubMed ID: 25494709
[TBL] [Abstract][Full Text] [Related]
16. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
17. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
[TBL] [Abstract][Full Text] [Related]
18. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines.
Braun HA; Umbreen S; Groll M; Kuckelkorn U; Mlynarczuk I; Wigand ME; Drung I; Kloetzel PM; Schmidt B
J Biol Chem; 2005 Aug; 280(31):28394-401. PubMed ID: 15919666
[TBL] [Abstract][Full Text] [Related]
19. Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle.
Koroleva ON; Pham TH; Bouvier D; Dufau L; Qin L; Reboud-Ravaux M; Ivanov AA; Zhuze AL; Gromova ES; Bouvier-Durand M
Biochimie; 2015 Jan; 108():94-100. PubMed ID: 25446655
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide causes Sp1 protein degradation by inducing a unique trypsin-like serine protease in rat lungs.
Ye X; Liu SF
Biochim Biophys Acta; 2007 Feb; 1773(2):243-53. PubMed ID: 17092579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
